Profil
Kelly O’Brien Wilson currently works at Forte Animal Health, Inc., as Director from 2020 and Biostax Corp., as Chief Operating Officer from 2022.
Ms. Wilson also formerly worked at Biostax Corp., as CTO & Director-Human Resources from 2015 to 2020, Biostax Corp., as Chief Executive & Operating Officer in 2023, and Cytocom, Inc., as Chief Technology & Information Officer from 2016 to 2020.
Ms. Wilson received her undergraduate degree and graduate degree from the University of Central Florida.
Aktive Positionen von Kelly Wilson
| Unternehmen | Position | Beginn |
|---|---|---|
| BIOSTAXPAR | Geschäftsführer | 01.08.2022 |
Forte Animal Health, Inc. | Direktor/Vorstandsmitglied | 01.12.2020 |
Ehemalige bekannte Positionen von Kelly Wilson
| Unternehmen | Position | Ende |
|---|---|---|
| BIOSTAXPAR | Vorstandsvorsitzender | 25.07.2023 |
| BIOSTAXPAR | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2020 |
Cytocom, Inc. /Old/
Cytocom, Inc. /Old/ BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company, which develops novel small molecule immunotherapies | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2020 |
Ausbildung von Kelly Wilson
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
University of Central Florida
University of Central Florida Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biostax Corp.
Biostax Corp. Pharmaceuticals: MajorHealth Technology Manufactures and develops pharmaceutical & biotechnology products | Health Technology |
Cytocom, Inc. /Old/
Cytocom, Inc. /Old/ BiotechnologyHealth Technology Operates as clinical-stage biopharmaceutical company, which develops novel small molecule immunotherapies | Health Technology |
Forte Animal Health, Inc. | Process Industries |
















